JPH0365500B2 - - Google Patents
Info
- Publication number
- JPH0365500B2 JPH0365500B2 JP58056142A JP5614283A JPH0365500B2 JP H0365500 B2 JPH0365500 B2 JP H0365500B2 JP 58056142 A JP58056142 A JP 58056142A JP 5614283 A JP5614283 A JP 5614283A JP H0365500 B2 JPH0365500 B2 JP H0365500B2
- Authority
- JP
- Japan
- Prior art keywords
- porphyrins
- blood
- heme
- extract
- protoporphyrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000004032 porphyrins Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 229950003776 protoporphyrin Drugs 0.000 claims description 12
- -1 protoporphyrin iron complex Chemical class 0.000 claims description 10
- 150000003973 alkyl amines Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 238000004445 quantitative analysis Methods 0.000 claims 1
- 150000003278 haem Chemical class 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 102000018146 globin Human genes 0.000 description 7
- 108060003196 globin Proteins 0.000 description 7
- MOTVYDVWODTRDF-UHFFFAOYSA-N 3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,22-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CC(O)=O)C(=CC=3C(=C(CC(O)=O)C(=C4)N=3)CCC(O)=O)N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 MOTVYDVWODTRDF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
- 229940025294 hemin Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NIUVHXTXUXOFEB-UHFFFAOYSA-N coproporphyrinogen III Chemical class C1C(=C(C=2C)CCC(O)=O)NC=2CC(=C(C=2C)CCC(O)=O)NC=2CC(N2)=C(CCC(O)=O)C(C)=C2CC2=C(C)C(CCC(O)=O)=C1N2 NIUVHXTXUXOFEB-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- GPRXGEKBQVXWAQ-UHFFFAOYSA-L disodium;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoate Chemical compound [Na+].[Na+].N1C(C=C2C(=C(C)C(=CC=3C(C)=C(CCC([O-])=O)C(N=3)=C3)N2)C=C)=C(C)C(C=C)=C1C=C1C(C)=C(CCC([O-])=O)C3=N1 GPRXGEKBQVXWAQ-UHFFFAOYSA-L 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
本発明は血液中のポルフイリン類の定量法に関
する。
血液中に存在するヘモグロビンはヘムと称され
るプロトポルフイリン鉄錯体と蛋白質グロビンと
の分子化合物である。また、血液中には、ヘムの
生合成の前駆体であるプロトポルフイリン、コプ
ロポルフイリノーゲンの代謝物であるコプロポル
フイリン、更にウロポルフイリン等が微量含まれ
ている。
これらのプロトポルフイリン鉄錯体(ヘム)、
プロトポルフイリン、コプロポルフイリン及びウ
ロポルフイリン(以下「ポルフイリン類」と総称
する)は生命維持に欠くことができないものであ
り、従つて生体中のこれらの量を正確に定量する
ことは、生体の代謝機能を知る上で、臨床的に極
めて重要なことである。すなわち、生体中のポル
フイリン類の量を測定することによつて、肝臓障
害あるいはポルフイリン代謝異常等を知ることが
できる。ポルフイリン代謝異常には先天性のもの
と、体外からの重金属又はハロゲン化合物の蓄積
によつて惹起するものとがあるが、これによつて
これら毒物の被蓄積度を測定することもできる。
しかしながら、従来ポルフイリン類の測定は、
尿中あるいは糞中及び血清中のそれを測定するの
が主であり、血球中のそれはヘモグロビンの影響
があるため困難であつた。
すなわち血液中のポルフイリン類を測定するに
は、これらを血液中から分離しなければならない
が、前述の如く、ヘムはグロビンと分子化合物を
形成しているので、これを分解してヘムをグロビ
ンから分離しなければならない。また、ヘムを遊
離させたとしても、これは酸性物質であるのに対
し、プロトポルフイリン、コプロポルフイリン及
びウロポルフイリンは両性物質であるため、これ
ら全てを同時に抽出することは困難である。
従来、ヘムを抽出する方法としては、Fischer
らによる氷酢酸法〔Org.Synth.21、53(1941)〕、
すなわち新鮮な血液を多量の熱氷酢酸と食塩で処
理してヘミンとして抽出する方法が知られてい
る。しかし、この方法ではヘミンは結晶として析
出させており、析出しなかつたヘミンは酢酸中に
残存するため定量的にヘムを分離抽出していると
はいえない。
また、プロトポルフイリン、コプロポルフイリ
ン及びウロポルフイリンを抽出する方法として
は、Grinsteinらの方法、すなわち酢酸と酢酸エ
チルを使用する方法及びこの改良法のPiomeriら
の方法が知られているが、この方法は測定者によ
るバラツキが大きく、満足できるものではなかつ
た。
以上、従来の方法は何れも酸性で抽出を行うた
め、酸性物質であるヘムを溶液状態で得ることは
できず、従つてポルフイリン類を同時に抽出し、
同時に定量することはできなかつた。
斯かる実情において、本発明者は、上記ポルフ
イリン類の全てを同時にしかも安定に抽出すべく
鋭意研究を行つた結果、ジ低級アルキルアミンを
含有する低級アルコールがヘモグロビンをヘムと
グロビンに分解すると共にヘム及びプロトポルフ
イリン、コプロポルフイリン、ウロポルフイリン
等のポルフイリン類を溶解し、蛋白グロビンを固
形物として沈澱させるので、ポルフイリン類を全
て同時に抽出できることを見出し、本発明を完成
した。
すなわち、本発明は、血液を、ジ低級アルキル
アミンを含有する低級アルコールにより抽出処理
して、ヘモグロビンから分解誘導したプロトポル
フイリン鉄錯体及び血液中に原始的に存在するポ
ルフイリン類を抽出し、その抽出物中のプロトポ
ルフイリン鉄錯体及びポルフイリン類の量を測定
することを特徴とする血液中のポルフイリン類の
定量方法である。
本発明を実施するには、先ず血液をジ低級アル
キルアミンを含有する低級アルコールに加えて混
合撹拌する。
ジ低級アルキルアミンとしてはジエチルアミ
ン、ジイソプロピルアミン等が、また低級アルコ
ールとしてはメタノール、エタノール、プロパノ
ール等が使用される。これらのうち、ジエチルア
ミンとメタノールの組合せが最も好ましい。ジ低
級アルキルアミンの濃度はその種類によつても異
なるが、一般には1.5〜3%程度が好適である。
混合撹拌は室温ないし50℃の温度で1分ないし1
時間行われる。このようにするとき、ヘモグロビ
ンの分子結合は切れてヘムとグロビンに分解し、
ヘムはヘマチンあるいはジ低級アルキルアミンが
配位した形で溶剤中に溶けて抽出され、同時に他
のポルフイリン類も抽出される。またグロビンは
固形物として沈澱するので、分離される。
次いで、斯くして得られる抽出液中のポルフイ
リン類の量を測定する。ポルフイリン類の測定は
従来公知の方法によつて行い得るが、就中高速液
体クロマトグラフイーを使用するのが好ましい。
例えば充填剤としてポーラスポリマースチレン系
ゲルを用い、展開溶媒として0.1N NaOH水溶液
−メタノール(1:9)を使用して高速液体クロ
マトグラフイーを行い、400nmの可視部の吸収で
ヘムを検出することが、また励起波長400nm、螢
光波長630nmの螢光検出でその他のポルフイリン
類を定量することができる。
次に実施例を挙げて説明する。
実施例 1
(i) ヘパリン処理した患者採血液を遠心分離し、
血球と血漿に分け、凍結保存しておいたもの
を、2℃で融解し、それぞれ50μを採取し
た。これに2.5%ジエチルアミンを含むメタノ
ール2mlを撹拌下加え、1分間振盪し、遠心分
離して上澄液を採取した。
(ii) 上記(i)で得た上澄液20μを高速液体クロマ
トグラフイーに付した〔充填剤:球状ポーラス
ポリマースチレン系ゲル、展開溶剤:0.1N
NaOH水溶液−メタノール(1:9)〕。ヘム
は400nmで検出し、その他のポルフイリン類は
励起波長400nm、螢光波長630nmの螢光で検出
した。
ポルフイリン類の各保持時間及び検量線は次の
とおりであつた。
ヘムのジエチルアミン体 6.5分 第1図
プロトポルフイリンナトリウム 15.3分 第2
図
コプロポルフイリンナトリウム 2分 第3図
ウロポルフイリンナトリウム 1分
結果は第1表のとおりである。尚ポルフイリン
類の量は血球及び血漿各100ml中の含量で示した。
The present invention relates to a method for quantifying porphyrins in blood. Hemoglobin present in blood is a molecular compound of a protoporphyrin iron complex called heme and the protein globin. Blood also contains small amounts of protoporphyrin, a precursor for heme biosynthesis, coproporphyrin, a metabolite of coproporphyrinogen, and uroporphyrin. These protoporphyrin iron complexes (heme),
Protoporphyrin, coproporphyrin, and uroporphyrin (hereinafter collectively referred to as "porphyrins") are indispensable for maintaining life, and therefore, accurately quantifying their amounts in the living body is essential for the metabolism of the living body. This is clinically extremely important in understanding its function. That is, by measuring the amount of porphyrins in a living body, liver damage or porphyrin metabolic abnormality can be detected. Porphyrin metabolic abnormalities include those that are congenital and those that are caused by the accumulation of heavy metals or halogen compounds from outside the body, and it is also possible to measure the degree of accumulation of these toxic substances. However, conventional measurements of porphyrins
The main method is to measure it in urine, feces, and serum, and it has been difficult to measure it in blood cells because it is affected by hemoglobin. In other words, in order to measure porphyrins in the blood, they must be separated from the blood, but as mentioned above, heme forms a molecular compound with globin, so this can be broken down to separate heme from globin. Must be separated. Further, even if heme is liberated, it is difficult to extract all of them at the same time because heme is an acidic substance, whereas protoporphyrin, coproporphyrin, and uroporphyrin are amphoteric substances. Traditionally, the method for extracting heme is Fischer
Glacial acetic acid method by et al. [Org.Synth.21, 53 (1941)],
Specifically, a method is known in which fresh blood is treated with a large amount of hot glacial acetic acid and salt to extract hemin. However, in this method, hemin is precipitated as crystals, and unprecipitated hemin remains in acetic acid, so it cannot be said that heme is quantitatively separated and extracted. In addition, as methods for extracting protoporphyrin, coproporphyrin, and uroporphyrin, the method of Grinstein et al., that is, the method using acetic acid and ethyl acetate, and the improved method of this method, the method of Piomeri et al., are known. There were large variations among the measurers, and the results were not satisfactory. As mentioned above, since all conventional methods perform extraction under acidic conditions, it is not possible to obtain heme, which is an acidic substance, in a solution state. Therefore, porphyrins are extracted at the same time.
It was not possible to quantify them simultaneously. Under these circumstances, the present inventor conducted intensive research to extract all of the above-mentioned porphyrins simultaneously and stably, and as a result, lower alcohols containing di-lower alkylamine decompose hemoglobin into heme and globin, and heme The present invention was completed based on the discovery that all porphyrins can be extracted simultaneously by dissolving porphyrins such as protoporphyrin, coproporphyrin, and uroporphyrin, and precipitating protein globin as a solid. That is, the present invention extracts protoporphyrin iron complex derived from hemoglobin and porphyrins originally present in blood by extracting blood with a lower alcohol containing a di-lower alkylamine. This is a method for quantifying porphyrins in blood, which is characterized by measuring the amount of protoporphyrin iron complex and porphyrins in an extract. To carry out the present invention, blood is first added to a lower alcohol containing a di-lower alkylamine and mixed and stirred. Diethylamine, diisopropylamine, etc. are used as the di-lower alkylamine, and methanol, ethanol, propanol, etc. are used as the lower alcohol. Of these, the combination of diethylamine and methanol is most preferred. The concentration of di-lower alkylamine varies depending on its type, but is generally preferably about 1.5 to 3%.
Mix and stir at room temperature to 50℃ for 1 minute to 1 minute.
Time is done. When this happens, the molecular bonds of hemoglobin are broken and it breaks down into heme and globin.
Heme is dissolved in a solvent in the form of hematin or di-lower alkylamine and is extracted, and other porphyrins are also extracted at the same time. The globin also precipitates as a solid and is therefore separated. Next, the amount of porphyrins in the extract thus obtained is measured. Porphyrins can be measured by conventionally known methods, but high performance liquid chromatography is preferably used.
For example, high-performance liquid chromatography is performed using porous polymer styrene gel as a filler and 0.1N NaOH aqueous solution - methanol (1:9) as a developing solvent, and heme is detected by absorption in the visible region of 400 nm. However, other porphyrins can also be quantified by fluorescence detection with an excitation wavelength of 400 nm and a fluorescence wavelength of 630 nm. Next, an example will be given and explained. Example 1 (i) Centrifuging heparinized patient blood collection,
Blood cells and plasma were separated and stored frozen, thawed at 2°C, and 50μ of each was collected. To this was added 2 ml of methanol containing 2.5% diethylamine under stirring, followed by shaking for 1 minute and centrifugation to collect the supernatant. (ii) 20μ of the supernatant obtained in (i) above was subjected to high performance liquid chromatography [filler: spherical porous polymer styrene gel, developing solvent: 0.1N
NaOH aqueous solution-methanol (1:9)]. Heme was detected at 400 nm, and other porphyrins were detected using fluorescence at an excitation wavelength of 400 nm and a fluorescence wavelength of 630 nm. The retention times and calibration curves for each porphyrin were as follows. Diethylamine form of heme 6.5 minutes Figure 1 Protoporphyrin sodium 15.3 minutes 2
Figure Coproporphyrin sodium 2 minutes Figure 3 Uroporphyrin sodium 1 minute The results are shown in Table 1. The amount of porphyrins was expressed as the content in each 100 ml of blood cells and plasma.
【表】【table】
Claims (1)
級アルコールにより抽出処理して、ヘモグロビン
から分解誘導したプロトポルフイリン鉄錯体及び
血液中に原始的に存在するポルフイリン類を抽出
し、その抽出物中のプロトポルフイリン鉄錯体及
びポルフイリン類の量を測定することを特徴とす
る血液中のポルフイリン類の定量方法。 2 抽出液中のプロトポルフイリン鉄錯体及びポ
ルフイリン類の量の測定が、抽出液を高速液体ク
ロマトグラフイーに付す方法である特許請求の範
囲第1項記載の定量法。[Scope of Claims] 1 Blood is extracted with a lower alcohol containing a di-lower alkylamine to extract protoporphyrin iron complex decomposed from hemoglobin and porphyrins originally present in the blood, 1. A method for quantifying porphyrins in blood, which comprises measuring the amount of protoporphyrin iron complex and porphyrins in the extract. 2. The quantitative method according to claim 1, wherein the amount of protoporphyrin iron complex and porphyrins in the extract is measured by subjecting the extract to high performance liquid chromatography.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5614283A JPS59180459A (en) | 1983-03-31 | 1983-03-31 | Quantitative analysis of porphyrin in blood |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5614283A JPS59180459A (en) | 1983-03-31 | 1983-03-31 | Quantitative analysis of porphyrin in blood |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59180459A JPS59180459A (en) | 1984-10-13 |
JPH0365500B2 true JPH0365500B2 (en) | 1991-10-14 |
Family
ID=13018823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5614283A Granted JPS59180459A (en) | 1983-03-31 | 1983-03-31 | Quantitative analysis of porphyrin in blood |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59180459A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755712B (en) * | 2014-01-16 | 2016-01-13 | 中山百灵生物技术有限公司 | Industrial extraction method of heme in sun-cured pig blood powder in slaughterhouse |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5977357A (en) * | 1982-09-13 | 1984-05-02 | リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・ミネソタ | Method of determining hemoglobin in biological sample |
-
1983
- 1983-03-31 JP JP5614283A patent/JPS59180459A/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5977357A (en) * | 1982-09-13 | 1984-05-02 | リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・ミネソタ | Method of determining hemoglobin in biological sample |
Also Published As
Publication number | Publication date |
---|---|
JPS59180459A (en) | 1984-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moyer et al. | Analysis for urinary catecholamines by liquid chromatography with amperometric detection: methodology and clinical interpretation of results. | |
Cotlove | Determination of the True Chloride Content of Biological Fluids and Tissues. II. Analysis by Simple, Nonisotopic Methods. | |
JPS5815738B2 (en) | A method for producing sebum using the sebum extract | |
CN111638106A (en) | Dry chemical analysis quality control substance for urine | |
Bergmann et al. | An improved assay with 4-(2-thiazolylazo)-resorcinol for non-esterified fatty acids in biological fluids | |
CN111999275B (en) | Method for rapidly and quantitatively measuring pH value and/or uric acid | |
JPH05133938A (en) | Method for separating glycosylated hemoglobin hb alc by agarose gel | |
JPS62253399A (en) | Determination of lipid-bonding sialic acid | |
CN114229827A (en) | Carbon nanodot, dual-mode probe prepared based on carbon nanodot and application of dual-mode probe | |
JP2843919B2 (en) | Analytical method using lithium salt as erythrocyte lysis and hemoglobin denaturing reagent | |
CN109520979B (en) | A kind of detection method of cholesterol in serum | |
Brodersen et al. | Separation and determination of bile pigments | |
Lumeng et al. | Microassay of pyridoxal phosphate using tyrosine apodecarboxylase | |
JPH0365500B2 (en) | ||
CN111304282A (en) | A detection kit for urine tyrosine | |
Rajagopal et al. | A new method for estimation of ethylene glycol in biological material | |
Sato et al. | Simultaneous separation and quantification of free and metal-chelated protoporphyrins in blood by three-dimensional HPLC | |
CN115779971A (en) | Cascade nanoenzyme and preparation method and application thereof | |
Lawrie | The excretion of l (—)-tyrosine in urine | |
JP3181390B2 (en) | Method for measuring protein saccharification ratio | |
Zhao et al. | Activity-based sensing reveals elevated labile copper promotes liver aging via hepatic ALDH1A1 depletion | |
Kurtin et al. | Assay of β-glucuronidase in bile following ion-pair extraction of pigments and bile acids | |
JP2632989B2 (en) | Method for measuring unsaturated iron binding ability | |
Zak et al. | Serum copper and iron on a single sample | |
JP3547879B2 (en) | Biochemical test method using sialyl sugar chain in fibrinogen and method for purifying fibrinogen |